Advanced Cancer Clinical Trials

A listing of 51 Advanced Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Advanced Cancer

37 - 48 of 51

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 51 active clinical trials seeking participants for Advanced Cancer research studies. The states with the highest number of trials for Advanced Cancer participants are Texas, California, Florida and New York.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Study

Recruiting

Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Allergic Asthma

Learn More

Featured Trial

Studying an Investigational Virus Vaccine

Recruiting

The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.

Conditions:

Healthy

Interested in vaccine studies

All Conditions

Preventative Trials

Learn More

Featured Trial

Type 2 Diabetes Clinical Trial

Recruiting

Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.

Conditions:

Type 2 Diabetes

Diabetes Mellitus Type 2 in Obese

Diabetes Type Two

Type 2 Diabetes Mellitus

Diabete Type 2

Learn More

A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors

NCT04419532

Recruiting

The purpose of this study is to assess the safety and tolerability of DS-1055a in participants with relapsed or refractory locally advanced or metastatic solid tumors for which no standard treatment is available.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

11/08/2024

Locations: Memorial Sloan Kettering Cancer Center, New York, New York +5 locations

Conditions: Solid Tumor, Advanced Cancer, Metastatic Solid Tumor

Learn More ›

A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors

NCT06190886

Recruiting

The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of PTX-912 in patients with locally advanced or metastatic solid tumors. To evaluate the PK and immunogenicity profile of PTX-912. To evaluate the preliminary anti-tumor activity of PTX-912. Participants will be treated with PTX-912 via iv infusion, every 2 weeks until progression of disease, unacceptable toxicity, or 12 months of total study therapy.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

11/04/2024

Locations: City of Hope National Medical Center, Duarte, California +2 locations

Conditions: Advanced Cancer, Solid Tumor, Metastatic Cancer

Learn More ›

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

NCT05735080

Recruiting

Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of INX-315 in patients with recurrent advanced/metastatic cancer, including hormone receptor positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer who progressed on a prior cyclin... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

10/25/2024

Locations: Emory Winship Cancer Institute, Atlanta, Georgia +6 locations

Conditions: Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Ovarian Cancer, CCNE1 Amplification, Solid Tumor, Advanced Cancer, Metastatic Cancer

Learn More ›

Psilocybin in Cancer Pain Study

NCT06001749

Recruiting

The overall objective of this study is to assess the feasibility, safety and preliminary efficacy of psilocybin-assisted therapy to alleviate opioid-refractory pain in patients with advanced-cancer. The name of the study intervention used in this research study is: Psilocybin (a tryptamine derivative)

Gender:

ALL

Ages:

18 years and above

Trial Updated:

10/14/2024

Locations: Dana-Farber Cancer Institute, Boston, Massachusetts

Conditions: Opioid-Related Disorders, Pain Management, Pain Management and Care, Advanced Cancer, Advanced Cancers

Learn More ›

A Study of Repotrectinib in Combination with Chemotherapy in Children and Young Adults with Solid Tumor Cancer

NCT05004116

Recruiting

This study will test the safety of the study drug, repotrectinib, in combination with chemotherapy (irinotecan and temozolomide) in children and young adults who have advanced or metastatic solid tumors. We researchers will try to find the highest dose of the study drug that causes few or mild side effects in study participants. When the researchers find this dose, we will evaluate it in a different group of participants to find out whether repotrectinib in combination with chemotherapy is an ef... Read More

Gender:

ALL

Ages:

Between 1 year and 25 years

Trial Updated:

10/01/2024

Locations: Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

Conditions: Advanced Cancer, Metastatic Solid Tumor

Learn More ›

Care Planning Framework in Advanced Cancer (ABC123)

NCT05408507

Recruiting

Pilot study assessing the feasibility and acceptability of the ABC123 framework, as well as goal concordance between patient and clinician stated goals. Patients \>60 years old with recently diagnosed advanced, incurable cancer in for a first consultation at a participating medical oncology clinic. The team will pilot test the ABC123 framework delivery by an advanced practice provider working with a medical oncologist to inform the overall care planning process. This framework will routinely inc... Read More

Gender:

ALL

Ages:

60 years and above

Trial Updated:

09/19/2024

Locations: University of Colorado Cancer Center, Aurora, Colorado

Conditions: Advanced Cancer

Learn More ›

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

NCT03785249

Recruiting

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

09/18/2024

Locations: ONeal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, Alabama +213 locations

ONeal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, Alabama

Alaska Oncology and Hematology, Anchorage, Alaska

Mayo Clinic Arizona - Phoenix Campus, Phoenix, Arizona

Local Institution - 001-807, Scottsdale, Arizona

Local Institution - 001-873-A, Tucson, Arizona

USOR - Arizona Oncology - Tucson - Rudasill, Tucson, Arizona

Local Institution - 001-840-B, Bellflower, California

Beverly Hills Cancer Center, Beverly Hills, California

City of Hope - Duarte (Main Campus), Duarte, California

Local Institution - 001-850-K, Dublin, California

Providence Medical Foundation - Virginia K. Crosson Cancer Center - Fullerton, Fullerton, California

Local Institution - 001-840-C, Harbor City, California

University of California San Diego Moores Cancer Center, La Jolla, California

TRIO - Cancer and Blood Specialty Clinic, Los Alamitos, California

Southern California Permanente Medical Group - Los Angeles Medical Center, Los Angeles, California

Valkyrie Clinical Trials, Los Angeles, California

Hoag Memorial Hospital Presbyterian - Newport Beach, Newport Beach, California

Local Institution - 001-850-B, Oakland, California

University of California Irvine Medical Center, Orange, California

Local Institution - 001-850-C, Roseville, California

Local Institution - 001-850-J, Sacramento, California

Local Institution - 001-850-D, Sacramento, California

California Cancer Associates for Research and Excellence (cCARE) - San Diego 4S Ranch, San Diego, California

Local Institution - 001-840-A, San Diego, California

Local Institution - 001-850-H, San Francisco, California

Local Institution - 001-850-E, San Francisco, California

Local Institution - 001-850-F, San Jose, California

Local Institution - 001-850-A, San Leandro, California

Ridley - Tree Cancer Center - Santa Barbara, Santa Barbara, California

Local Institution - 001-850-I, Santa Clara, California

Local Institution - 001-884-A, Solvang, California

Kaiser Permanente - Vallejo Medical Center, Vallejo, California

Local Institution - 001-850-G, Walnut Creek, California

USOR - Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado

UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, Colorado

Local Institution - 001-872-H, Boulder, Colorado

Local Institution - 001-872-E, Colorado Springs, Colorado

Local Institution - 001-872-B, Denver, Colorado

Local Institution - 001-951 - A, Denver, Colorado

Local Institution - 001-951 - B, Denver, Colorado

Cancer Centers of Colorado - St. Marys Regional Hospital, Grand Junction, Colorado

SCL Health - Saint Joseph Hospital Cancer Center, Lafayette, Colorado

Local Institution - 001-872-A, Lakewood, Colorado

Local Institution - 001-872-D, Littleton, Colorado

Local Institution - 001-872-K, Lone Tree, Colorado

Local Institution - 001-872-C, Longmont, Colorado

Local Institution - 001-872-J, Parker, Colorado

Local Institution - 001-872-F, Pueblo, Colorado

Local Institution - 001-872-G, Pueblo, Colorado

Local Institution - 001-872-I, Thornton, Colorado

Yale Cancer Center, New Haven, Connecticut

USOR - Medical Oncology Hematology Consultants, Newark, Delaware

Local Institution - 001-929i, Altamonte Springs, Florida

Boca Raton Clinical Research Associates, Inc., Boca Raton, Florida

Local Institution - 001-929c, Brandon, Florida

Local Institution - 001-929g, Clearwater, Florida

Local Institution - 001-926b, Daytona Beach, Florida

SCRI - Florida Cancer Specialists - South Region Research Office, Fort Myers, Florida

Local Institution - 001-929b, Gainesville, Florida

Mayo Clinic - Jacksonville, Jacksonville, Florida

Local Institution - 001-929m, Lady Lake, Florida

Local Institution - 001-929e, Largo, Florida

Local Institution - 001-929n, Lecanto, Florida

Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida

Miami Cancer Institute, Miami, Florida

Florida Cancer Affiliates - Ocala - Main, Ocala, Florida

Local Institution - 001-929p, Ocala, Florida

Local Institution - 001-929j, Orange City, Florida

Mid Florida Cancer Centers - Orange City, Orange City, Florida

Local Institution - 001-929l, Orlando, Florida

Woodlands Medical Specialists, Pensacola, Florida

Local Institution - 001-929a, Saint Petersburg, Florida

SCRI - Florida Cancer Specialists - North Region Research Office, Saint Petersburg, Florida

Local Institution - 001-929h, Spring Hill, Florida

Local Institution - 001-926d, Stuart, Florida

Local Institution - 001-929d, Tampa, Florida

Local Institution - 001-929k, Tavares, Florida

Local Institution - 001-929f, Trinity, Florida

Local Institution - 001-926c, Vero Beach, Florida

Local Institution - 001-926a, Wellington, Florida

SCRI - Florida Cancer Specialists - East Region Research Office, West Palm Beach, Florida

Local Institution - 001-929o, Winter Park, Florida

University Cancer & Blood Center (UCBC) - Athens, Athens, Georgia

Local Institution - 001-835-C, Austell, Georgia

Local Institution - 001-835-E, Austell, Georgia

Local Institution - 001-835-D, Carrollton, Georgia

Local Institution - 001-835-F, Carrollton, Georgia

Local Institution - 001-835-A, Cartersville, Georgia

Local Institution - 001-835-B, Douglasville, Georgia

Northwest Georgia Oncology Centers Wellstar - Marietta, Marietta, Georgia

Affiliated Oncologists - Millenium Medical Center - Chicago Ridge, Chicago Ridge, Illinois

Local Institution - 001-828, Chicago, Illinois

USOR - Illinois Cancer Specialists - Niles, Niles, Illinois

Memorial Hospital, South Bend, Indiana

University of Iowa, Iowa City, Iowa

University of Kansas Medical Center, Westwood, Kansas

University of Kentucky, Lexington, Kentucky

SCRI - Hematology Oncology Clinic - Baton Rouge, Baton Rouge, Louisiana

MaineHealth Cancer Care - Biddeford, Biddeford, Maine

Local Institution - 001-881-B, Brandywine, Maryland

Maryland Oncology Hematology - Columbia, Columbia, Maryland

Local Institution - 001-881-A, Silver Spring, Maryland

Dana-Farber Cancer Institute, Boston, Massachusetts

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

Henry Ford Health System, Detroit, Michigan

Local Institution - 001-842-A, Farmington Hills, Michigan

Local Institution - 001-838-F, Coon Rapids, Minnesota

Local Institution - 001-838-E, Edina, Minnesota

Local Institution - 001-875 - D, Edina, Minnesota

Local Institution - 001-838-D, Maplewood, Minnesota

Local Institution - 001-875 - A, Maplewood, Minnesota

Local Institution - 001-838-C, Minneapolis, Minnesota

USOR - Minnesota Oncology - Minneapolis Clinic, Minneapolis, Minnesota

Local Institution - 001-838-G, Minneapolis, Minnesota

Local Institution - 001-822-A, Minneapolis, Minnesota

Masonic Cancer Center, Minneapolis, Minnesota

Mayo Clinic - Rochester, Rochester, Minnesota

Metro-Minnesota Community Oncology Research Consortium (MMCORC), Saint Louis Park, Minnesota

Local Institution - 001-838-B, Saint Louis Park, Minnesota

Local Institution - 001-838-A, Saint Paul, Minnesota

Local Institution - 001-875 - B, Saint Paul, Minnesota

Local Institution - 001-875 - C, Woodbury, Minnesota

Central Care Cancer Center - Bolivar, Bolivar, Missouri

Goldschmidt Cancer Center, Jefferson City, Missouri

Sisters of Charity of Leavenworth Health St. Marys, Billings, Montana

Local Institution - 001-544B, Omaha, Nebraska

Methodist Estabrook Cancer Center, Omaha, Nebraska

Local Institution - 001-544A, Omaha, Nebraska

University of Nebraska Medical Center, Omaha, Nebraska

Local Institution - 001-860A, Henderson, Nevada

Local Institution - 001-860C, Henderson, Nevada

Local Institution - 001-860B, Henderson, Nevada

USOR - Comprehensive Cancer Centers of Nevada - Southeast Henderson, Henderson, Nevada

Local Institution - 001-860E, Las Vegas, Nevada

Local Institution - 001-860D, Las Vegas, Nevada

Local Institution - 001-860F, Las Vegas, Nevada

New York Oncology Hematology - Albany Medical Center, Albany, New York

Roswell Park Comprehensive Cancer Center, Buffalo, New York

Local Institution - 001-832, Lake Success, New York

Perlmutter Cancer Center - 34th Street, New York, New York

Local Institution - 001-583, New York, New York

Memorial Sloan Kettering Cancer Center - New York, New York, New York

University of North Carolina Hospitals, Chapel Hill, North Carolina

FirstHealth Outpatient Cancer Center, Pinehurst, North Carolina

The Christ Hospital, Cincinnati, Ohio

University of Cincinnati Health Barrett Cancer Center, Cincinnati, Ohio

Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio

Local Institution - 001-833 - H, Columbus, Ohio

Local Institution - 001-833 - C, Columbus, Ohio

Local Institution - 001-833 - J, Columbus, Ohio

Local Institution - 001-833 - A, Columbus, Ohio

Local Institution - 001-833 - F, Columbus, Ohio

The Ohio State University College of Medicine, Columbus, Ohio

Local Institution - 001-833 - D, Columbus, Ohio

Local Institution - 001-833 - I, Columbus, Ohio

SCRI - Mark H. Zangmeister Cancer Center, Columbus, Ohio

Local Institution - 001-833 - B, Columbus, Ohio

Local Institution - 001-833 - G, Columbus, Ohio

Local Institution - 001-833 - E, Gahanna, Ohio

Kettering Health Cancer Center - Main Campus, Kettering, Ohio

Local Institution - 001-836-A, Kettering, Ohio

Cancer Centers of Southwest Oklahoma - Leah M. Fitch Cancer Center, Lawton, Oklahoma

Local Institution - 001-580, Oklahoma City, Oklahoma

Local Institution - 001-584, Tulsa, Oklahoma

Local Institution - 001-586-A, Bend, Oregon

St. Charles Health System, Bend, Oregon

Willamette Valley Cancer Institute and Research Center - Eugene, Eugene, Oregon

Lehigh Valley Physician Group Hematology Oncology, Allentown, Pennsylvania

Local Institution - 001-837-A, Bethlehem, Pennsylvania

Penn State Cancer Institute, Hershey, Pennsylvania

USOR - Alliance Cancer Specialists - Media (Cancer Center at Riddle Memorial Hospital), Media, Pennsylvania

USOR - Charleston Hematology Oncology Associates, Charleston, South Carolina

Medical University of South Carolina, Charleston, South Carolina

Local Institution - 001-801-G, Gallatin, Tennessee

Local Institution - 001-801-A, Hendersonville, Tennessee

Local Institution - 001-801-D, Hermitage, Tennessee

Local Institution - 001-801-F, Murfreesboro, Tennessee

Local Institution - 001-801-B, Nashville, Tennessee

Tennessee Oncology - Nashville - Centennial Clinic - Medical Oncology, Nashville, Tennessee

Local Institution - 001-801-E, Nashville, Tennessee

Local Institution - 001-801-C, Nashville, Tennessee

Local Institution - 001-888-B, Arlington, Texas

USOR - Texas Oncology Dallas Fort Worth West (DFWW) - Arlington South, Arlington, Texas

USOR - Texas Oncology - Austin Central, Austin, Texas

Local Institution - 001-848a, Conroe, Texas

Mary Crowley Cancer Research - Medical City Hospital, Dallas, Texas

USOR - Texas Oncology - Dallas Fort Worth (DFW) - Presbyterian Cancer Center Dallas, Dallas, Texas

USOR - Texas Oncology - Dallas Fort Worth (DFW) - Baylor Charles A. Sammons Cancer Center, Dallas, Texas

USOR - Texas Oncology Northeast Texas - Denison, Denison, Texas

Texas Oncology - Dallas Fort Worth (DFW) - Fort Worth, Fort Worth, Texas

Oncology Consultants - Texas Medical Center, Houston, Texas

University of Texas MD Anderson Cancer Center, Houston, Texas

Local Institution - 001-935A, Houston, Texas

Local Institution - 001-999, Irving, Texas

Local Institution - 001-935D, Kingwood, Texas

Lumi Research, Kingwood, Texas

USOR - Texas Oncology - Midland Allison Cancer Center, Midland, Texas

START Center for Cancer Care, San Antonio, Texas

Local Institution - 001-935B, Shenandoah, Texas

Local Institution - 001-935C, Spring, Texas

Texas Oncology - Sugar Land, Sugar Land, Texas

Local Institution - 001-935E, Tomball, Texas

Texas Oncology - Northeast Texas Cancer and Research Institute - Tyler, Tyler, Texas

Texas Oncology - Waco, Waco, Texas

Local Institution - 001-919, Fairfax, Virginia

NEXT Virginia, Fairfax, Virginia

Hematology Oncology Associates of Fredericksburg, Fredericksburg, Virginia

USOR - Virginia Oncology Associates - Newport News, Newport News, Virginia

Local Institution - 001-882-A, Norfolk, Virginia

Virginia Cancer Institute - West End, Richmond, Virginia

Fred Hutchinson Cancer Research Center, Seattle, Washington

USOR - Northwest Cancer Specialists, P.C. dba Compass Oncology - Vancouver Cancer Center, Vancouver, Washington

University Wisconsin Carbone Cancer Center, Madison, Wisconsin

PanOncology Trials - Rio Piedras Medical Center, San Juan, Not set

Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease

Learn More ›

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

NCT03175224

Recruiting

To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resis... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/08/2024

Locations: Loma Linda University Medical Center, Loma Linda, California +90 locations

Loma Linda University Medical Center, Loma Linda, California

University of Southern California / Norris Comprehensive Cancer Center, Los Angeles, California

Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California

Kaiser Permanente - CA, Riverside, California

UCSF - Helen Diller Family Comprehensive Cancer Center, San Francisco, California

Providence Medical Foundation, Santa Monica, California

Providence St. Joseph Health, Santa Rosa, California

Kaiser Permanente - Vallejo, Vallejo, California

Christiana Hospital, Newark, Delaware

Florida Cancer Specialists - South, Fort Myers, Florida

Miami Cancer Institute, Miami, Florida

Florida Cancer Specialists - North, Saint Petersburg, Florida

Florida Cancer Specialists, Tallahassee, Florida

Moffitt, Tampa, Florida

Florida Cancer Specialists, West Palm Beach, Florida

Maryland Oncology Hematology, Silver Spring, Maryland

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Dana Farber Cancer Institute, Boston, Massachusetts

Mayo Clinic, Rochester, Minnesota

HealthPartners Cancer Research Center, Saint Louis Park, Minnesota

Washington University School of Medicine, Saint Louis, Missouri

University of North Carolina, Chapel Hill, North Carolina

Wake Forest University Health Sciences, Winston-Salem, North Carolina

The Ohio State University (OSU), Columbus, Ohio

Ohio Health Research Institute, Columbus, Ohio

Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania

St. Francis Cancer Center, Greenville, South Carolina

Sarah Cannon and HCA Research Institute, Nashville, Tennessee

The Don & Sybil Harrington Cancer Center, Amarillo, Texas

West Virginia University Cancer Institute, Morgantown, West Virginia

University of Wisconsin, Madison, Wisconsin

Flinders Medical Centre, Bedford Park, South Australia

Border Medical Oncology, Albury, Not set

Peninsula and Southeast Oncology, Frankston, Not set

St Vincents Hospital Melbourne, Melbourne, Not set

Sir Charles Gairdner Hospital, Nedlands, Not set

Calvary Central Districts Hospita, North Adelaide, Not set

Lady Davis Institute for Medical Research Jewish General Hospital, Montreal, Quebec

Cross Cancer Institute, Edmonton, Not set

McGill University Health Center - Research Institute, Montréal, Not set

Princess Margaret Hospital, Toronto, Not set

Cancer Care Manitoba, Winnipeg, Not set

Tampere University Hospital, Tampere, Not set

CHRU de Brest - Hôpital Morvan, Brest, Not set

CHRU de Lille, Lille, Not set

Centre Leon Berard, Lyon, Not set

Centre d'Essais Precoces en Cancerologie de Marseille, Marseille, Not set

Hopital Bichat - Claude Bernard - AP-HP, Paris, Not set

CHU Rennes - Hopital Pontchaillou, Rennes, Not set

Gustave Roussy, Villejuif, Not set

Orszagos Koranyi Pulmonologiai Intezet, Budapest, Not set

Szent Borbala Korhaz, Tatabanya, Not set

Torokbalinti Tudogyogyintezet, Torokbalint, Not set

Azienda Ospedaliero-Universitaria delle Marche, Ancona, Not set

IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola, Bologna, Not set

Azienda Ospedaliero Universitaria Policlinico G. Rodolico-San Marco - Presidio Ospedaliero G. Rodolico, Catania, Not set

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Not set

Istituto Europeo di Oncologia, Milano, Not set

IRCCS Ospedale San Raffaele, Milan, Not set

Istituto Oncologico Veneto-I.R.C.C.S. - Ospedale Busonera, Padova, Not set

AOU Citta della Salute e della Scienza di Torino - Ospedale le Molinette, Torino, Not set

PanOncology Trials, LLC, Rio Piedras, Not set

Arkhangelsk Clinical Oncological Dispensary, Arkhangelsk, Not set

JSC Group of companies Medsi, Otradnoye, Not set

Private Medical Institution Euromedservice, Saint Petersburg, Not set

Saint-Petersburg Clinical Research Center of Specialized Types of Medical Care (Oncology), Saint Petersburg, Not set

Ogarev Mordovia State University, Saransk, Not set

JSC Current Medical Technologies, St. Petersburg, Not set

Volgograd Regional Clinical Oncology Dispensary, Volgograd, Not set

National Cancer Centre Singapore, Singapore, Not set

Oncocare Cancer Centre, Singapore, Not set

Tan Tock Seng Hospital, Singapore, Not set

Hospital Germans Trias i Pujol, Badalona, Not set

Hospital Clinic Barcelona, Barcelona, Not set

Hospital del Mar, Barcelona, Not set

Institut Catala d'Oncologia - L'Hospitalet, Barcelona, Not set

Hospital General Universitario Gregorio Maranon, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Not set

Hospital Universitario Ramon y Cajal, Madrid, Not set

Hospital Universitario Central de Asturias, Oviedo, Not set

Hospital Universitario Virgen del Rocio, Sevilla, Not set

Instituto Valenciano de Oncologia, Valencia, Not set

Taichung Veterans General Hospital, Taichung, Not set

Chi-Mei Hospital - Liouying Branch, Tainan, Not set

National Taiwan University Hospital, Taipei City, Not set

Linkou Chang Gung Memorial Hospital (CGMHLK), Taoyuan City, Not set

Imperial College Healthcare NHS Trust, London, Not set

University College London Hospital, London, Not set

The Christie NHS Foundation Trust, Manchester, Not set

Royal Marsden Hospital - Surrey, Surrey Quays, Not set

Conditions: Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, Solid Tumors, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping

Learn More ›

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

NCT05394103

Recruiting

Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/08/2024

Locations: Mayo Clinic, Phoenix, Arizona +8 locations

Conditions: Advanced Cancer, Metastatic Cancer

Learn More ›

MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer

NCT05076760

Recruiting

This phase I trial is designed in two parts. First as an open-label, dose escalation trial of MEM-288 monotherapy in which investigators aim to find the maximum tolerated dose (MTD) and recommended phase II dose (RP2D). Subjects with selected solid tumors including non-small cell lung cancer (NSCLC) who have a tumor lesion which is accessible for injection will undergo intratumoral injection of MEM-288. Following completion of the monotherapy study portion of the study, an expansion arm is desig... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/28/2024

Locations: Moffitt Cancer Center, Tampa, Florida +1 locations

Conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer

Learn More ›

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

NCT04354246

Recruiting

Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/10/2024

Locations: Florida Cancer Specialists, Sarasota, Florida +8 locations

Conditions: Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC

Learn More ›

Lenvatinib in Locally Advanced Invasive Thyroid Cancer

NCT04321954

Recruiting

This research is being done to evaluate the safety and efficacy of neoadjuvant lenvatinib on surgical outcomes of patients with invasive extrathyroidal differentiated thyroid cancer (DTC). This research study involves a study drug called lenvatinib

Gender:

ALL

Ages:

18 years and above

Trial Updated:

11/01/2023

Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +2 locations

Conditions: Differentiated Thyroid Cancer, Advanced Cancer

Learn More ›

37 - 48 of 51